Grant Number:	5P20CA210677-02 Interpret this number
Primary Investigator:	Campbell, Thomas
Organization:	University Of Colorado Denver
Project Title:	African Center for the Advancement of Research Excellence (AFRICARE)
Fiscal Year:	2018

PROJECT SUMMARY (Overall) Human health in Zimbabwe is threatened by non-communicable diseases including cancer and cardiovascular diseases. Despite the contribution of NCDs to poor health outcomes in Zimbabwe, there are limited evidence- based national guidelines for the management of major NCDs through primary care approaches. The goal of this P20 planning grant application is to establish the "Initiative for a Non-communicable disease Centre of Research Excellence in Zimbabwe (AfriCARE)" at the University of Zimbabwe College of Health Sciences (UZCHS) to facilitate the research needed to establish evidence-based approaches to improve prevention, diagnosis and treatment of cancer and cardiovascular disease, and thereby decrease mortality from these NCDs in Zimbabwe and the southern African region. The long term goal of AfriCARE is to increase the quality, quantity and impact of research in cancer and cardiovascular disease. This will be accomplished by increasing scientific collaborations in these diseases between investigators at UZCHS and investigators in high income countries; strengthening the capacity of investigators at UZCHS to conduct cutting edge research to better understand the epidemiology and pathogenesis, and improve diagnosis and treatment of cancer and cardiovascular disease in Zimbabwe; and establishing the evidence base needed to inform public health policy to improve care of these diseases in Zimbabwe.




Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients.
Authors: Nyangwara V.A. , Mazhindu T. , Chikwambi Z. , Masimirembwa C. , Campbell T.B. , Borok M. , Ndlovu N. .
Source: British journal of clinical pharmacology, 2024 Aug; 90(8), p. 1782-1789.
EPub date: 2023-01-27.
PMID: 36630266
Related Citations

Metabolic and cardiovascular disease risk for Zimbabwean men with prostate cancer receiving long-term androgen deprivation therapy.
Authors: Mazhindu T. , Ndlovu N. , Borok M.Z. , Meki S. , Nyamhunga A. , Havranek E.P. , Kessler E.R. , Campbell T.B. , Flaig T.W. .
Source: Research square, 2023-12-12; , .
EPub date: 2023-12-12.
PMID: 38168443
Related Citations

Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
Authors: Mbavha B.T. , Thelingwani R.S. , Chikwambi Z. , Nyakabau A.M. , Masimirembwa C. , the Consortium for Genomics and Therapeutics in Africa .
Source: British journal of clinical pharmacology, 2023 Oct; 89(10), p. 3209-3216.
EPub date: 2023-06-26.
PMID: 37337448
Related Citations

Warfarin pharmacogenetics in a black Zimbabwean cohort: an observational prospective study.
Authors: M Hidjo M.M. , Chikwambi Z. , Ngwende G. , Matenga J.A. , Masimirembwa C. .
Source: Pharmacogenomics, 2023 Jul; 24(10), p. 529-538.
EPub date: 2023-07-12.
PMID: 37435666
Related Citations

Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
Authors: Chikondowa P. , Munkombwe D. , Chikwambi Z. , Kuona P. , Masimirembwa C. .
Source: Pharmacogenomics, 2023 Jun; 24(8), p. 449-457.
EPub date: 2023-05-30.
PMID: 37248698
Related Citations

Pharmacogenetics of pain management in Zimbabwean patients with sickle cell disease.
Authors: Mapira N.L. , Thelingwani R.S. , Chikwambi Z. , Kuona P. , Masimirembwa C. .
Source: Pharmacogenomics, 2023 May; 24(7), p. 359-369.
EPub date: 2023-05-30.
PMID: 37248824
Related Citations

Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe.
Authors: Afolabi B.L. , Mazhindu T. , Zedias C. , Borok M. , Ndlovu N. , Masimirembwa C. , On Behalf Of Consortium For Genomics And Therapeutics In Africa Cgta null .
Source: Journal of personalized medicine, 2023-03-28; 13(4), .
EPub date: 2023-03-28.
PMID: 37108974
Related Citations